-
First New Treatment in Decades for Parkinson’s “Off” Episodes Awaits FDA Approval`
If the FDA approves Sunovion’s APL-130277 come January, Parkinson’s patients will have a first oral treatment — and a first new treatment in more than a decade — for off episodes, those times of difficulties with movement despite taking treatments that stimulate dopamine receptors, like levodopa.
Click here to learn more about what this means for people living with Parkinson’s.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.